MedTrace Logo

Rifaximin SSD in Dementia Trial

NCT06718686 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-04-03

No results posted yet for this study

Summary

Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.

Conditions

  • Dementia Alzheimer Type
  • Dementia Associated With Cerebrovascular Disease

Interventions

DRUG

Rifaximin SSD 40 mg IR tablet

Drug therapy vs placebo

DRUG

Placebo

Placebo drug

Sponsors & Collaborators

  • Bausch Health Americas, Inc.

    collaborator INDUSTRY

  • Jasmohan Bajaj

    lead FED

Principal Investigators

  • Jasmohan Bajaj · Richmond VA Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-30
Primary Completion
2027-10-30
Completion
2027-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06718686 on ClinicalTrials.gov